Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (ENHANCE)

Complete title: Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC 122 and the Combinations of CC-122 and Ibrutinib and CC-122 and Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Research Study Number 9597
 
Principal Investigator Mazyar Shadman
 
Phase I/II

Research Study Description

Safety, pharmacokinetics, and preliminary efficacy of CC-122 alone and in combination with ibrutinib and obinuzutumab.

CC-122 has multiple activities, including immune modulation of several immune cell subsets and antiproliferative activity in CLL. CC-122 has also been shown to have a tolerable safety profile with some preliminary signs of efficacy with early human experience.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 9597
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Leukemia, Chronic Lymphocytic (CLL); Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disorders; Neoplasms; Leukemia, Lymphoid; Immunoproliferative Disorders; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Immune System Diseases; Immunotherapy

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials